Skip to content

FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer.

Oct 2026 · Nuclear Medicine and Biology · Vol 162-163, pp. 109840 · 0 citations · 20 references
Medicine

TL;DR

This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.

Abstract

Background

Advanced lung cancer remains a major therapeutic challenge, with limited efficacy of single-agent therapies. Fibroblast activation protein-targeted radioligand therapy (FAP-RLT) induces tumor-specific DNA damage, which may prime the cGAS-STING innate immune pathway. We explored whether [177Lu]Lu-FAP-2286 (FAP-RLT) synergizes with the STING agonist diABZI to enhance antitumor immunity in FAP-positive lung cancer.

Methods

An immunocompetent C57BL/6 Lewis lung carcinoma model with stable FAP overexpression, designated LLC-FAP, was established. Tumor targeting of [177Lu]Lu-FAP-2286 was evaluated by ex vivo biodistribution. Mice were treated with PBS, [177Lu]Lu-FAP-2286 alone, diABZI alone, or combination therapy. Antitumor efficacy was assessed by tumor volume measurement and survival analysis. Mechanistic studies included immunohistochemistry of IFN-β expression, CD8+ T-cell infiltration and tumor cell apoptosis biomarkers.

Results

[177Lu]Lu-FAP-2286 showed excellent tumor targeting (9.8 ± 1.3%ID/g at 4 h post-injection) and induced DNA damage (γ-H2AX: +318.9%)/STING upregulation (H-score: +52.0%). The combination therapy yielded superior antitumor activity, resulting in a 50.3 ± 14.8% tumor volume reduction at short-term efficacy evaluation and a prolonged median survival of 45.6 ± 6.3 days, compared with 34.1 ± 4.3 days for the STINGa monotherapy group (P < 0.001)and 22.6 ± 2.3 days for the [177Lu]Lu-FAP-2286 monotherapy group (P < 0.001). Mechanistically, the combination significantly enhanced CD8+ T-cell infiltration in tumors compared with the STINGa monotherapy group (24.5 ± 1.4% vs. 9.9 ± 0.1% of CD45+ cells, P = 0.003) and the [177Lu]Lu-FAP-2286 monotherapy group (24.5 ± 1.4% vs.7.5 ± 0.4% of CD45+ cells, P < 0.001). This effect was accompanied by elevated IFN-β expression and promoted tumor cell apoptosis. No overt treatment-related toxicity was observed in major organs.

Conclusions

[177Lu]Lu-FAP-2286 acts as a potent immune sensitizer for STING agonist therapy. This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.

View source

Similar papers

Open access Oct 2026

Preclinical Evaluation of 177Lu-Labeled PSMA and FAP Bispecific Radioligand for Prostate Cancer

Background/Objectives: During prostate cancer progression, downregulation or loss of prostate-specific membrane antigen (PSMA) expression, together with interlesional heterogeneity, may limit the efficacy of PSMA-targeted radioligand therapy. Fibroblast activation protein (FAP), expressed mainly by activated cancer-ass...

R. Xue, Ya-Chao Liu, Xin-Lin Wang et al. · 0 citations
Oct 2026

Integrated [68Ga]Ga-FAPI-7ND PET/CT and stromal profiling of immunocompetent syngeneic tumor models for FAP-targeted radionuclide therapy.

In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.

Hui-Jie Li, Yu-Ling Zhang, Xin-Yin Ren et al. · 0 citations
Oct 2026

Design and Biological Evaluation of FAP-Man, a Mannosylated FAP-Targeted Radioglycopeptide for Tumor Imaging and Radionuclide Therapy.

Fibroblast activation protein (FAP) is an attractive target for radiotheranostic development because of its abundant expression in tumor-associated fibroblasts and limited distribution in normal tissues. Here, we developed FAP-Man, a mannosylated FAP-targeted radioglycopeptide based on the FAP-2286 scaffold, to optimiz...

Miao-Miao Song, En-Tao Liu, Rui Cao et al. · 0 citations
Open access Nov 2026

Pharmacokinetic and dosimetric evaluation of [177Lu]Lu-FAPI for stromal-targeted radionuclide therapy in triple-negative breast cancer: a preclinical biodistribution and dosimetry study

Triple-negative breast cancer (TNBC) has limited targeted treatment options and is strongly influenced by stromal biology. This study evaluated [ 177 Lu]Lu-FAPI for fibroblast activation protein-alpha (FAP)-directed tumor microenvironment targeting in TNBC models. [ 177 Lu]Lu-FAPI was assessed usin...

Zhi-Hua Tang, Lu-Shan Yu, Ke Zhang · 0 citations
Oct 2026

A 177Lu-labeled Inetetamab theranostic conjugate with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy of HER2-positive breast cancer.

PURPOSE HER2-positive breast cancer requires targeted therapies that overcome resistance and desmoplastic barriers. This study aimed to develop and biologically evaluate a 177Lu-labeled Inetetamab conjugate (177Lu-Inetetamab) with dual cytotoxic and stromal-depleting activities for targeted radionuclide therapy. METH...

Jian-Ping Zheng, Yu Zhang, Qing-Qing Li et al. · 0 citations
Open access Oct 2026

68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma

Purpose Hepatocellular carcinoma (HCC) remains a major clinical challenge due to its high recurrence rate, poor response to systemic therapies, and unfavorable prognosis. Human epidermal growth factor receptor 3 (HER3) has emerged as a clinically relevant molecular target in HCC. Seribantumab is a fully human IgG2 mono...

Jiao-Jiao Li, Xiao Yang, Aodungerile Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.